FMP
Gemini Therapeutics, Inc.
GMTX
NASDAQ
Inactive Equity
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
1.35 USD
0 (0%)
About
ceo
N/A
sector
Healthcare
industry
Biotechnology
website
https://www.geminitherapeutics.com
exchange
NASDAQ
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
CIK
0001816736
ISIN
US36870G1058
CUSIP
36870G105
Address
300 One Kendall Square
Phone
212 600 1902
Country
US
Employee
24
IPO Date
Aug 12, 2020
Key Executives
